Early alterations of brain cellular energy homeostasis in huntington disease models

Journal of Biological Chemistry

Volumn 287, Issue 2, 2012, Pages 1361-1370

  Mochel, Fanny ^a,b,c   Durant, Brandon ^c   Meng, Xingli ^c   O'Callaghan, James ^d   Yu, Hua ^e   Brouillet, Emmanuel ^f   Wheeler, Vanessa C ^g   Humbert, Sandrine ^e   Schiffmann, Raphael ^e   Durr, Alexandra ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^e INSERM U1005   (France)

^f INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTES; ATP DEPLETION; ATP LEVEL; CELLULAR ENERGY; CREATINE KINASE; ENERGY DEFICIT; ENZYMATIC ACTIVITIES; FRONTAL CORTEX; HIGH ENERGY PHOSPHATES; HUNTINGTON DISEASE; IN-VIVO; LOW-ENERGY STATE; MICROWAVE FIXATION; MOTOR SYSTEMS; NEURODEGENERATIVE; PROTEIN KINASE; STRIATUM; TRANSGENICS;

BRAIN MODELS; ENZYMES; HIGH ENERGY PHYSICS; MAMMALS; NEURODEGENERATIVE DISEASES; PHOSPHATES; PHOSPHORYLATION; PHYSIOLOGY; RNA;

BRAIN;

CREATINE PHOSPHATE; CREATININE; GUANIDINOACETATE METHYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAG REPEAT; CELL ENERGY; CONTROLLED STUDY; CORPUS STRIATUM; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INACTIVATION; FRONTAL CORTEX; HIPPOCAMPUS; HOMEOSTASIS; HUNTINGTON CHOREA; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ADENOSINE TRIPHOSPHATE; ANIMALS; BRAIN CHEMISTRY; CONVULSANTS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FRONTAL LOBE; GENE KNOCK-IN TECHNIQUES; GUANIDINOACETATE N-METHYLTRANSFERASE; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NITRO COMPOUNDS; PHOSPHOCREATINE; PROPIONIC ACIDS;

MUS;

EID: 84855481293     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M111.309849     Document Type: Article

References (47)

1. Gusella, J. F., Wexler, N. S., Conneally, P. M., Naylor, S. L., Anderson, M. A., Tanzi, R. E., Watkins, P. C., Ottina, K., Wallace, M. R., and Sakaguchi, A. Y. (1983) A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306, 234-238
2. The Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983
3. Ciarmiello, A., Cannella, M., Lastoria, S., Simonelli, M., Frati, L., Rubinsztein, D. C., and Squitieri, F. (2006) Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington's disease. J. Nucl. Med. 47, 215-222
4. Mochel, F., and Haller, R. G. (2011) Energy deficit in Huntington disease: why it matters. J. Clin. Invest. 121, 493-499
5. Milakovic, T., and Johnson, G. V. (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem. 280, 30773-30782
6. Powers, W. J., Videen, T. O., Markham, J., McGee-Minnich, L., Antenor- Dorsey, J. V., Hershey, T., and Perlmutter, J. S. (2007) Selective defect of in vivo glycolysis in early Huntington's disease striatum. Proc. Natl. Acad. Sci. U.S.A. 104, 2945-2949
7. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., and Krainc, D. (2006) Transcriptional repression of PGC-1α by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127, 59-69
8. Beal, M. F. (1994) Neurochemistry and toxin models in Huntington's disease. Curr. Opin. Neurol. 7, 542-547
9. Brouillet, E., Jacquard, C., Bizat, N., and Blum, D. (2005) 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J. Neurochem. 95, 1521-1540
10. Lowry, O. H., Passonneau, J. V., Hasselberger, F. X., and Schulz, D. W. (1964) Effect of ischemia on known substrates and cofactors of the glycolytic pathway in brain. J. Biol. Chem. 239, 18-30
11. Scharf, M. T., Mackiewicz, M., Naidoo, N., O'Callaghan, J. P., and Pack, A. I. (2008) AMP-activated protein kinase phosphorylation in brain is dependent on method of killing and tissue preparation. J. Neurochem. 105, 833-841
12. Delaney, S. M., and Geiger, J. D. (1996) Brain regional levels of adenosine and adenosine nucleotides in rats killed by high-energy focused microwave irradiation. J. Neurosci. Methods 64, 151-156
13. Gines, S., Seong, I. S., Fossale, E., Ivanova, E., Trettel, F., Gusella, J. F., Wheeler, V. C., Persichetti, F., and MacDonald, M. E. (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet. 12, 497-508
14. Weydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., Cui, L., Beyer, R. P., Easley, C. N., Smith, A. C., Krainc, D., Luquet, S., Sweet, I. R., Schwartz, M. W., and La Spada, A. R. (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1α in Huntington's disease neurodegeneration. Cell Metab. 4, 349-362
15. van der Burg, J. M., Bacos, K., Wood, N. I., Lindqvist, A., Wierup, N., Woodman, B., Wamsteeker, J. I., Smith, R., Deierborg, T., Kuhar, M. J., Bates, G. P., Mulder, H., Erlanson-Albertsson, C., Morton, A. J., Brundin, P., Petersén, A., and Björkqvist, M. (2008) Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis. 29, 41-51
16. Mochel, F., Charles, P., Seguin, F., Barritault, J., Coussieu, C., Perin, L., Le Bouc, Y., Gervais, C., Carcelain, G., Vassault, A., Feingold, J., Rabier, D., and Durr, A. (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2, e647
17. Wheeler, V. C., Auerbach, W., White, J. K., Srinidhi, J., Auerbach, A., Ryan, A., Duyao, M. P., Vrbanac, V., Weaver, M., Gusella, J. F., Joyner, A. L., and MacDonald, M. E. (1999) Length-dependent gametic CAG repeat instability in the Huntington's disease knock-in mouse. Hum. Mol. Genet. 8, 115-122
18. Lee, J. M., Pinto, R. M., Gillis, T., St Claire, J. C., and Wheeler, V. C. (2011) Quantification of age-dependent somatic CAG repeat instability in Hdh CAG knock-in mice reveals different expansion dynamics in striatum and liver. PLoS One 6, e23647
19. Dragileva, E., Hendricks, A., Teed, A., Gillis, T., Lopez, E. T., Friedberg, E. C., Kucherlapati, R., Edelmann, W., Lunetta, K. L., MacDonald, M. E., and Wheeler, V. C. (2009) Intergenerational and striatal CAG repeat instability in Huntington's disease knock-in mice involve different DNA repair genes. Neurobiol. Dis. 33, 37-47
20. O'Callaghan, J. P., and Sriram, K. (2004) Focused microwave irradiation of the brain preserves in vivo protein phosphorylation: comparison with other methods of sacrifice and analysis of multiple phosphoproteins. J. Neurosci. Methods 135, 159-168
21. 2+ ATPase activity using high-performance liquid chromatography. Anal. Biochem. 372, 135-139
22. Braissant, O., Henry, H., Villard, A. M., Speer, O., Wallimann, T., and Bachmann, C. (2005) Creatine synthesis and transport during rat embryogenesis: spatiotemporal expression of AGAT, GAMTand CT1.BMC Dev. Biol. 5, 9
23. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85
24. Morton, A. J., Glynn, D., Leavens, W., Zheng, Z., Faull, R. L., Skepper, J. N., and Wight, J. M. (2009) Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol. Dis. 33, 331-341
25. Chan, P., DeLanney, L. E., Irwin, I., Langston, J. W., and Di Monte, D. (1991) Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. J. Neurochem. 57, 348-351
26. Seong, I. S., Ivanova, E., Lee, J. M., Choo, Y. S., Fossale, E., Anderson, M., Gusella, J. F., Laramie, J. M., Myers, R. H., Lesort, M., and MacDonald, M. E. (2005) HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum. Mol. Genet. 14, 2871-2880
27. Snell, R. G., MacMillan, J. C., Cheadle, J. P., Fenton, I., Lazarou, L. P., Davies, P., MacDonald, M. E., Gusella, J. F., Harper, P. S., and Shaw, D. J. (1993) Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4, 393-397
28. Oláh, J., Klivényi, P., Gardián, G., Vécsei, L., Orosz, F., Kovacs, G. G., Westerhoff, H. V., and Ovádi, J. (2008) Increased glucose metabolism and ATP level in brain tissue of Huntington's disease transgenic mice. FEBS J. 275, 4740-4755
29. Thu, D. C., Oorschot, D. E., Tippett, L. J., Nana, A. L., Hogg, V. M., Synek, B. J., Luthi-Carter, R., Waldvogel, H. J., and Faull, R. L. (2010) Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 133, 1094-1110
30. Kaltenbach, L. S., Romero, E., Becklin, R. R., Chettier, R., Bell, R., Phansalkar, A., Strand, A., Torcassi, C., Savage, J., Hurlburt, A., Cha, G. H., Ukani, L., Chepanoske, C. L., Zhen, Y., Sahasrabudhe, S., Olson, J., Kurschner, C., Ellerby, L. M., Peltier, J. M., Botas, J., and Hughes, R. E. (2007) Huntingtin interacting proteins are genetic modifiers of neurodegenera- tion. PLoS Genet. 3, e82
31. Steele, A. D., Jackson, W. S., King, O. D., and Lindquist, S. (2007) The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases. Proc. Natl. Acad. Sci. U.S.A. 104, 1983-1988
32. Rudenko, O., Tkach, V., Berezin, V., and Bock, E. (2009) Detection of early behavioral markers of Huntington's disease in R6/2 mice employing an automated social home cage. Behav. Brain Res. 203, 188-199
33. Dedeoglu, A., Kubilus, J. K., Yang, L., Ferrante, K. L., Hersch, S. M., Beal, M. F., and Ferrante, R. J. (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 85, 1359-1367
34. Ferrante, R. J., Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Kuemmerle, S., Kubilus, J. K., Kaddurah-Daouk, R., Hersch, S. M., and Beal, M. F. (2000) Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20, 4389-4397
35. Andreassen, O. A., Jenkins, B. G., Dedeoglu, A., Ferrante, K. L., Bogdanov, M. B., Kaddurah-Daouk, R., and Beal, M. F. (2001) Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. 77, 383-390
36. Yang, L., Calingasan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., and Beal, M. F. (2009) Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J. Neurochem. 109, 1427-1439
37. Verbessem, P., Lemiere, J., Eijnde, B. O., Swinnen, S., Vanhees, L., Van Leemputte, M., Hespel, P., and Dom, R. (2003) Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61, 925-930
38. Tabrizi, S. J., Blamire, A. M., Manners, D. N., Rajagopalan, B., Styles, P., Schapira, A. H., and Warner, T. T. (2005) High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 64, 1655-1656
39. Tkac, I., Dubinsky, J. M., Keene, C. D., Gruetter, R., and Low, W. C. (2007) Neurochemical changes in Huntington R6/2 mouse striatum detected by in vivo 1H NMR spectroscopy. J. Neurochem. 100, 1397-1406
40. Zhang, S. F., Hennessey, T., Yang, L., Starkova, N. N., Beal, M. F., and Starkov, A. A. (2011) Impaired brain creatine kinase activity in Huntington's disease. Neurodegener. Dis. 8, 194-201
41. Weiss, R. G., Chatham, J. C., Georgakopolous, D., Charron, M. J., Wallimann, T., Kay, L., Walzel, B., Wang, Y., Kass, D. A., Gerstenblith, G., and Chacko, V. P. (2002) An increase in the myocardial PCr/ATP ratio in GLUT4 null mice. FASEB J. 16, 613-615
42. Kim, J., Amante, D. J., Moody, J. P., Edgerly, C. K., Bordiuk, O. L., Smith, K., Matson, S. A., Matson, W. R., Scherzer, C. R., Rosas, H. D., Hersch, S. M., and Ferrante, R. J. (2010) Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochim. Biophys. Acta 1802, 673-681
43. Lin, Y. S., Chen, C. M., Soong, B. W., Wu, Y. R., Chen, H. M., Yeh, W. Y., Wu, D. R., Lin, Y. J., Poon, P. W., Cheng, M. L., Wang, C. H., and Chern, Y. (2011) Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. J. Clin. Invest. 121, 1519-1523
44. 2+ responses in muscles with combined mitochondrial and cytosolic creatine kinase deficiencies. Cell 89, 93-103
45. in 't Zandt, H. J., Renema, W. K., Streijger, F., Jost, C., Klomp, D. W., Oerlemans, F., Van der Zee, C. E., Wieringa, B., and Heerschap, A. (2004) Cerebral creatine kinase deficiency influences metabolite levels and morphology in the mouse brain: a quantitative in vivo 1H and 31P magnetic resonance study. J. Neurochem. 90, 1321-1330
46. Saks, V., Dos Santos, P., Gellerich, F. N., and Diolez, P. (1998) Quantitative studies of enzyme-substrate compartmentation, functional coupling and metabolic channelling in muscle cells. Mol. Cell Biochem. 184, 291-307
47. Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R., and Beal, M. F. (1998) J. Neurosci. 18, 156-163